Alzheimer's Disease Research Center- Supplement 3.2- Mark Bernard 2022

阿尔茨海默病研究中心 - 补充 3.2 - 马克·伯纳德 2022

• 批准号: 10610048
• 负责人: THOMAS M WISNIEWSKI
• 金额: $ 13.31万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10610048
• 关键词: Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Area; Autopsy; Behavioral; Biological Assay; Biological Markers; Cerebrospinal Fluid; Clinical; Clinical Data; Cognitive; Collaborations; Communities; Counseling; Cyclotrons; Data Linkages; Data Set; Dementia; Development; Diagnosis; Diagnostic Services; Early Diagnosis; Education; Fostering; Funding; Goals; Health; Heterogeneity; Impaired cognition; Infrastructure; Intervention; Investigation; Laboratories; Magnetic Resonance Imaging; Measures; Mental Depression; Methodology; Mission; Neuropsychology; New York; Participant; Pathology; Patients; Performance; Phenotype; Plasma; Population; Positron-Emission Tomography; Proteomics; Psychological Impact; Radiochemistry; Research; Role; Scanning; Scientist; Secure; Statistical Data Interpretation; Stress; Techniques; Therapeutic Intervention; Time; Training; Training and Education; Translational Research; Universities; Update; Work; aged; aging brain; biomarker development; cognitive function; cognitive testing; community setting; data management; disease heterogeneity; education research; epidemiology study; improved; in vivo; induced pluripotent stem cell; innovation; mild cognitive impairment; neuroimaging; neuroimaging marker; neuropathology; next generation; normal aging; novel; novel marker; novel therapeutic intervention; outreach; posters; prevent; programs; psychosocial; recruit; social factors; sociodemographic variables; tau Proteins; therapeutically effective

Since its inception in 1990, the Alzheimer's Disease Research Center (ADRC) at New York University Langone Health has facilitated pioneering research to define transitions from normal aging to the subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early dementia stages of AD; as well as AD biomarker development. Here we propose to continue this long-standing successful research direction with a focus on understanding disease heterogeneity and delineating biomarkers and their role in these transitions, with the long-term goal of helping to develop novel interventions that will delay or prevent cognitive decline. The NYU ADRC has built an infrastructure that supports innovative research on AD and related dementias (ADRD) to help achieve the NAPA goal of a cure by 2025. This will be facilitated by our nine highly successful and interactive Cores (Admin; Clinical; Data Management & Statistical [DMS]; Neuropathology; Outreach, Education & Engagement [ORE]; Neuroimaging; Biomarker; Psychosocial; and Research Education Component [REC]). Together, our highly integrated cores will achieve the following aims: Aim 1. Enhance the performance of innovative research in ADRC by maintaining nine cores that focus on delineating biomarkers of the transitions from normal aging to SCD, MCI, and early dementia, and determining their roles to help develop novel interventions that delay or prevent these transitions. We will also facilitate training in this area. Aim 2. Contribute to the national network of ADRCs by providing clinical data, autopsy diagnoses, neuroimaging and biosamples to NACC and NCRAD, as well as to other research community collaborative efforts in ADRD. Aim 3. Recruit and retain a diverse subject population from clinical and community settings, via the ORE and Psychosocial Cores, with concomitant engagement of the local scientific and lay community in ADRD with seminars, poster sessions and the developmental projects via the Admin, ORE, and REC Cores. Aim 4. Foster the development of novel avenues of investigation with methodological developments by the cores (via innovative cognitive assessments, neuroimaging techniques, biomarkers and proteomic approaches), and encourage, recruit, and select developmental projects. Aim 5. Accelerate translational research across the ADRD spectrum by using biomarkers to better define the underlying disease heterogeneity and foster the development of novel therapeutic interventions that consider this heterogeneity. Aim 6. Facilitate the education and training of a diverse ADRD workforce. Our Center will enhance the scientific community's understanding of ADRD and expand the next generation of diverse ADRD scientists, via combined efforts of the Admin, ORE, and REC Cores. In summary, the NYU ADRD has facilitated pioneering research that defined the stage transitions from normal aging to dementia, and contributed to AD biomarker development from its inception. In the next five years of funding, this focus will be expanded by: 1) improving our understanding of disease heterogeneity; 2) identifying new biomarkers that will allow early detection; and 3) fostering research that will develop effective therapeutic interventions.

自1990年成立以来，位于纽约大学朗格尼分校的阿尔茨海默病研究中心（ADRC） 健康促进了开创性的研究，以定义从正常衰老到主观认知的转变。 AD的认知功能减退（SCD）、轻度认知障碍（MCI）和早期痴呆阶段;以及AD生物标志物 发展在这里，我们建议继续这一长期成功的研究方向，重点是 了解疾病异质性，描绘生物标志物及其在这些转变中的作用， 长期目标是帮助开发新的干预措施，以延缓或预防认知能力下降。 纽约大学ADRC已经建立了一个基础设施，支持AD和相关痴呆症的创新研究 （ADRD）帮助实现到2025年实现治愈的国家适应行动方案目标。这将有助于我们的九个非常成功的 和交互式核心（管理;临床;数据管理和统计[DMS];神经病理学;外展， 教育和参与[ORE];神经影像学;生物标志物;心理社会;和研究教育组件 [REC]）。我们高度集成的内核将共同实现以下目标：目标1.增强性能 ADRC的创新研究，保持九个核心，重点是描绘生物标志物的转变 从正常衰老到SCD，MCI和早期痴呆，并确定它们的作用，以帮助开发新的 延迟或阻止这些转变的干预措施。我们还将促进这方面的培训。目标2.贡献 通过提供临床数据、尸检诊断、神经成像和生物样本， NACC和NCRAD，以及ADRD中的其他研究界合作努力。目标3.招募和 通过ORE和Psychosocial Cores，从临床和社区环境中保留多样化的受试者人群， 与当地科学界和非专业人士共同参与ADRD的研讨会，海报会议 以及通过Admin、ORE和REC核心的开发项目。目标4。促进小说的发展 核心研究方法发展的调查途径（通过创新的认知评估， 神经成像技术，生物标志物和蛋白质组学方法），并鼓励，招募和选择 发展项目。目标5。通过使用，加速ADRD范围内的转化研究 生物标志物，以更好地定义潜在的疾病异质性，并促进新的治疗药物的开发 考虑到这种异质性的干预措施。目标6。促进多样化ADRD的教育和培训 劳动力我们的中心将加强科学界对ADRD的理解，并扩大下一个 通过管理员、ORE和REC核心的共同努力，产生不同的ADRD科学家。总的来说， 纽约大学ADRD促进了开创性的研究，定义了从正常衰老到 痴呆，并从一开始就为AD生物标志物的发展做出了贡献。在未来五年的融资中， 重点将扩大：1）提高我们对疾病异质性的理解; 2）确定新的生物标志物 这将使早期发现;和3）促进研究，将开发有效的治疗干预措施。